294373001: Allergy to zalcitabine (finding)

• SNOMED CT Concept\Clinical finding (finding)\...
• \The disposition to develop an allergic or pseudoallergic reaction, the reaction itself or its consequences.\A propensity to developing an adverse reaction upon exposure to an agent at a dose otherwise tolerated by normal individuals. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to drug\Allergy to reverse transcriptase inhibitor\Allergy to zalcitabine
• \The disposition to develop an allergic or pseudoallergic reaction, the reaction itself or its consequences.\The disposition to develop an allergic reaction, the allergic reaction itself or its consequences.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to drug\Allergy to reverse transcriptase inhibitor\Allergy to zalcitabine
• \Propensity to adverse reaction\A propensity to developing an adverse reaction upon exposure to an agent at a dose otherwise tolerated by normal individuals. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to drug\Allergy to reverse transcriptase inhibitor\Allergy to zalcitabine
• \Propensity to adverse reaction\Propensity to adverse reactions to drug\Allergy to drug\Allergy to reverse transcriptase inhibitor\Allergy to zalcitabine

Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2006. Module: SNOMED CT core

Descriptions:

Id	Description	Lang	Type	Status	Case?	Module
434647015	Zalcitabine allergy	en	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
3750381019	Allergy to zalcitabine	en	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
3750399010	Allergy to zalcitabine (finding)	en	Fully specified name	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
746851000172112	allergie à la zalcitabine	fr	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT Switzerland NRC maintained Module

Expanded Value Set

Reference Sets

Description inactivation indicator reference set

GB English

US English

Back to Start